ArticleFrontiers in medicine2020
Antifibrotics in COVID-19 Lung Disease: Let Us Stay Focused.
Article in Frontiers in medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 30 citations in OpenAlex.
- Investigating the effect of pirfenidone on lung CT scans in patients with severe COVID-19 Hospitalized at Shahid Sadoughi Hospital, Yazd, Iran.Caspian journal of internal medicine · 2026Article
- Pulmonary Function Among COVID-19 Patients in Home Isolation Program.Medical sciences (Basel, Switzerland) · 2025Article
- Post-COVID-19 Pulmonary Fibrosis: Facts-Challenges and Futures: A Narrative Review.Pulmonary therapy · 2023Review
- Pulmonary fibrosis: A short- or long-term sequelae of severe COVID-19?Chinese medical journal pulmonary and critical care medicine · 2023Review
- Pharmacological approaches to pulmonary fibrosis following COVID-19.Frontiers in pharmacology · 2023Review
- Effect of Pirfenidone on Risk of Pulmonary Fibrosis in COVID-19 Patients Experiencing Cytokine Storm.Healthcare (Basel, Switzerland) · 2022Article
- Review
- Histopathological and molecular links of COVID-19 with novel clinical manifestations for the management of coronavirus-like complications.Inflammopharmacology · 2022Review
- Home monitoring of lung function, symptoms and quality of life after admission with COVID-19 infection: The HOMECOMIN' study.Respirology (Carlton, Vic.) · 2022Article
- COVID-19 therapeutics: Challenges and directions for the future.Proceedings of the National Academy of Sciences of the United States of America · 2022Review
- Severe Pulmonary Hypertension: An Important Sequel After Severe Post-Acute COVID-19 Pneumonia.Current problems in cardiology · 2022Review
- Immune interventions in COVID-19: a matter of time?Mucosal immunology · 2022Review
- Respiratory Complications after COVID-19.Oman medical journal · 2022Review
- Post-COVID syndrome: pulmonary complicationsTurkish journal of medical sciences · 2021Review
- Comparison of pirfenidone and corticosteroid treatments at the COVID-19 pneumonia with the guide of artificial intelligence supported thoracic computed tomography.International journal of clinical practice · 2021Article
- Extension of Collagen Deposition in COVID-19 Post Mortem Lung Samples and Computed Tomography Analysis Findings.International journal of molecular sciences · 2021Article
- Post-COVID-19 Pulmonary Fibrosis: Novel Sequelae of the Current Pandemic.Journal of clinical medicine · 2021Review
- Commentary: Antifibrotics in COVID-19 Lung Disease: Let Us Stay Focused.Frontiers in medicine · 2020Article
- Role of antifibrotic drugs in the management of post-COVID-19 interstitial lung disease: A review of literature and report from an expert working group.Lung India : official organ of Indian Chest SocietyArticle
- LTSI Consensus Guidelines: Preoperative Pulmonary Evaluation in Adult Liver Transplant Recipients.Journal of clinical and experimental hepatologyArticle
Corrections and comments
- Commented on by
- Erratum issued
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
Abstract
After decades of research, two therapies for chronic fibrotic lung disease are now approved by the FDA, with dozens more anti-fibrotic therapies in the pipeline. A great deal of enthusiasm has been generated for the use of these drugs, which are by no means curative but clearly have a favorable impact on lung function decline over time. Amidst a flurry of newly developed and repurposed drugs to treat the coronavirus disease 2019 (COVID-19) and its accompanying acute respiratory distress syndrome (ARDS), few have emerged as effective. Historically, survivors of severe viral pneumonia and related acute lung injury with ARDS often have near full recovery of lung function. While the pathological findings of the lungs of patients with COVID-19 can be diverse, current reports have shown significant lung fibrosis predominantly in autopsy studies. There is growing enthusiasm to study anti-fibrotic therapy for inevitable lung fibrosis, and clinical trials are underway using currently FDA-approved anti-fibrotic therapies. Given the relatively favorable outcomes of survivors of virus-mediated ARDS and the low prevalence of clinically meaningful lung fibrosis in survivors, this perspective examines if there is a rationale for testing these repurposed antifibrotic agents in COVID-19-associated lung disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.